Core Insights - Daxing Biopharmaceutical Industry Base has achieved significant milestones, including being recognized as a national-level "Green Industrial Park" and a five-star national new-type industrialization demonstration base, with plans for expansion and development in the biopharmaceutical sector [1][2][8] Group 1: Development Milestones - In 2021, Daxing Biopharmaceutical Industry Base was approved for a 9.1 square kilometer expansion, marking its entry into the trillion-level industrial park category [1] - The base was awarded the title of "Green Industrial Park" in 2022 and has been recognized for its innovative development strategies [1][2] - The construction of the new campus for Capital Medical University commenced in 2023, enhancing the collaborative innovation framework of "medical education, research, and production" [1][8] Group 2: Expansion Projects - The first industrial land project in the southern expansion area, the Ande Medical Health Industry Park, broke ground in February 2025, with a total investment of approximately 300 million yuan [7] - The northern expansion area, covering 5.5 square kilometers, focuses on living and service facilities, with the new campus of Capital Medical University as a key project [8] - During the "14th Five-Year Plan" period, the base completed 12 transactions for industrial land, emphasizing high-standard planning before construction [8] Group 3: Industry Focus and Innovation - The base has established a "3+5" industrial development roadmap, focusing on traditional Chinese medicine, vaccines, and high-end medical devices, while also exploring emerging fields like cell and gene therapy [10][11] - Daxing has become a hub for vaccine production, housing leading companies in the sector, and has transitioned from "following innovation" to "original breakthroughs" [10] - The base is also strengthening its position in high-end medical devices, with advancements in surgical robots and innovative medical implants [11] Group 4: Service and Support for Enterprises - Daxing Biopharmaceutical Industry Base provides comprehensive services for enterprises, including project site selection, business registration, environmental assessments, and policy applications [14] - A one-stop service platform has been established, integrating government services and industry resources, which has facilitated over 26,000 services to enterprises [14] - The base has organized various events to enhance collaboration and visibility for enterprises, leading to successful international market expansions for over 20 companies [15] Group 5: Future Outlook - The base aims to further optimize its industrial system by focusing on the "3+2+N" model, which includes strengthening existing industries and exploring new potential sectors [17] - The "15th Five-Year Plan" emphasizes the development of new productive forces and high-quality economic growth, aligning with Daxing's strategic goals [17] - Daxing Biopharmaceutical Industry Base is committed to continuing its role as a key player in the biopharmaceutical industry, with plans for further expansion and innovation [17]

Core Viewpoint - The pharmaceutical industry is undergoing a digital transformation driven by policy advancements and competitive dynamics, which is essential for upgrading the industry and enhancing core competitiveness [2]. Group 1: Industry Background - The digital transformation in the pharmaceutical industry is a key force for industrial upgrading and discovering new growth opportunities, supporting the implementation of the Healthy China strategy [2]. - The Ministry of Industry and Information Technology and other departments issued the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)", marking a critical phase for the industry [2]. Group 2: Company Overview - Beijing Lianxin Pharmaceutical Co., Ltd. was established in 1999 and produces artificial musk, a national class I new drug, which has supported the production of over 500 traditional Chinese medicine varieties [3]. - The company is committed to innovation and modernization, actively promoting its "smart transformation and digital upgrade" strategy [3]. Group 3: Transformation Challenges - The pharmaceutical industry faces significant challenges in regulatory compliance, high difficulty, and long cycles, complicating the transformation process for companies like Lianxin [4]. - Key challenges include data silos, low data transparency, and a lack of digital transformation experience, which hinder the transition from traditional to modern production systems [4][5]. Group 4: Schneider Electric's Role - Schneider Electric recognizes the strategic significance of Lianxin's transformation and aims to optimize production, energy, and equipment management through digital upgrades [6]. - The company employs a phased approach to implement upgrades, utilizing tools like EcoConsult and the AVEVA PI System to enhance data integration and operational efficiency [7][8]. Group 5: Digital Transformation Implementation - The AVEVA PI System will break down data silos and facilitate proactive quality risk management by integrating various production-related data [8]. - The EMS+ system will establish a comprehensive energy management framework, optimizing energy efficiency and operational performance [9]. - The introduction of MES and automated batch control systems will enable lean production and refined management, ensuring consistent product quality [10]. Group 6: Significance of the Case - Schneider Electric's expertise in electrification, automation, and digitalization supports Lianxin's production line upgrades, enhancing quality, efficiency, and cost-effectiveness [11]. - Lianxin's digital transformation sets a benchmark in the industry, promoting sustainable and compliant smart pharmaceutical practices [12]. - The company aims to deepen digital applications and enhance decision-making quality, operational efficiency, and cost control, contributing to high-quality development in the pharmaceutical industry [12].